申请人:Spectrum Pharmaceuticals, Inc.
公开号:US06770638B2
公开(公告)日:2004-08-03
Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.
本发明揭示了含有与芳基哌嗪及其衍生物相连的四氢吲哚酮的制药复合物组合物。具体地,揭示了用于治疗抗精神病障碍的复合物组合物。本发明中揭示的复合物组合物能够有效地缓解症状和治疗精神疾病,而不会导致认知功能下降。通常,复合物化合物由两个部分组成,部分A和部分B,其中四氢吲哚酮包含一个部分A,通过连接子L连接到一个部分B,其中B是芳基哌嗪基团。复合物化合物通过与GABA、血清素和多巴胺受体的相互作用提供抗精神病活性。具有综合活性的复合分子将提供治疗精神和神经疾病而不会导致认知障碍。